SNDX - シンダックス・ファ―マシュ―ティカルズ (Syndax Pharmaceuticals Inc.)

SNDXのニュース

   Syndax Pharmaceuticals, Inc. 2019 Q1 - Results - Earnings Call Slides  2019-05-06
The following slide deck was published by Syndax Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more …
   Syndax Pharmaceuticals' (SNDX) CEO Briggs Morrison on Q1 2019 Results - Earnings Call Transcript  2019-05-06
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2019 Earnings Release and Conference Call May 6, 2019 4:30 PM ET Company Participants Melissa Forst Argot Partners-Vice President Briggs Morrison Chief Executive Officer Michael Metzger President and Chief Operatin…
   Syndax down 4% on updated entinostat data  2019-04-01
Thinly traded micro cap Syndax Pharmaceuticals ( SNDX -4.4% ) slips on below-average volume on the heels of updated results from a Phase 1b/2 clinical trial, ENCORE 601 , evaluating HDAC inhibitor entinostat plus Merck's ( MRK +0.1% ) Keytruda (pembrolizumab) in patients with solid tu…
   Syndax Pharmaceuticals Presents Updated Phase 2 Data from ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2019 Annual Meeting  2019-04-01 PR Newswire
WALTHAM, Mass. , April 1, 2019 /PRNewswire/ --Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the presentation of updated findings from th…

calendar